HomeAI · summaries
Storia in 6 fonti
Sionna's surprise cystic fibrosis trial failure sinks hopes of challenging Vertex
Sionna Therapeutics’ shares fell more than 90% after reporting that its lead asset failed an early study and it is no longer advancing the experimental treatment going forward. Vertex's shares hit an all-time high at one point.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Sionna cystic fibrosis drug fails key trial, removing threat to Vertex
Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising analysts and collapsing company shares.
- ·
statnews.com
Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial
A pill from Sionna Therapeutics provided no added benefit when combined with Vertex's cystic fibrosis blockbuster Trikafta, a blow to the biotech.
